Edwards Lifesciences Corporation
EW · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -5.41 | 14.63 | 0.65 |
| FCF Yield | 0.66% | 1.36% | 2.06% | 1.74% |
| EV / EBITDA | 24.32 | 29.85 | 23.52 | 42.63 |
| Quality | ||||
| ROIC | 10.72% | 15.49% | 20.09% | 18.97% |
| Gross Margin | 79.46% | 79.30% | 78.31% | 76.57% |
| Cash Conversion Ratio | 0.13 | 0.64 | 0.80 | 1.15 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.35% | -1.44% | 7.06% | 6.37% |
| Free Cash Flow Growth | -53.95% | -33.97% | -32.01% | 116.74% |
| Safety | ||||
| Net Debt / EBITDA | -1.36 | -0.29 | -0.04 | -0.09 |
| Interest Coverage | 69.63 | 81.10 | 64.98 | 64.94 |
| Efficiency | ||||
| Inventory Turnover | 1.03 | 1.15 | 1.33 | 1.69 |
| Cash Conversion Cycle | 339.27 | 312.59 | 258.05 | 201.86 |